This concerted approach - the synergistic inhibition of mangiferin and curcumin as enhanced nano-drugs - has the potential to redefine therapeutic strategies for PI3K/Akt/mTOR pathway-mediated ovarian cancer. This evidence concerns the gene MTOR and ovarian carcinoma.